by Virtus | Jun 28, 2026 | Early-Stage Respiratory Drug Development
Respiratory drug discovery is the foundation of every new treatment developed for asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, viral respiratory infections and other lung diseases. Before a medicine reaches clinical trials, researchers...
by Virtus | Jun 28, 2026 | Early-Stage Respiratory Drug Development
COPD drug development is one of the most active areas of respiratory research as scientists work to develop new therapies for chronic obstructive pulmonary disease. COPD affects hundreds of millions of people worldwide and remains a leading cause of illness and...
by Virtus | Jun 6, 2026 | Early-Stage Respiratory Drug Development
Asthma drug development plays a critical role in improving outcomes for millions of people living with asthma worldwide. Despite significant advances in treatment, asthma remains a complex and highly variable respiratory disease that continues to drive demand for...
by Virtus | Jun 6, 2026 | Early-Stage Respiratory Drug Development
Respiratory drug development is a complex process that transforms scientific discoveries into therapies for patients with respiratory diseases. From asthma and COPD to viral respiratory infections, developing new respiratory medicines requires a combination of...
by Virtus | May 3, 2026 | Early-Stage Respiratory Drug Development
Respiratory CRO UK vs global CRO is a common comparison for biotech and pharmaceutical companies planning preclinical respiratory studies. Respiratory drug development requires disease-specific expertise, validated models, and reliable in vivo respiratory studies,...
by Virtus | May 3, 2026 | Early-Stage Respiratory Drug Development
Respiratory CRO services support biotech and pharmaceutical companies developing therapies for asthma, COPD, and viral respiratory diseases by delivering specialist preclinical respiratory studies. A respiratory preclinical CRO provides disease-specific models, in...
